ClinicalTrials.gg
RecruitingNCT07328451Updated Jul 1, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease

A Phase 1 interventional study of DNL628 and Placebo in Alzheimer Disease, Early Onset, sponsored by Denali Therapeutics Inc.. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Denali Therapeutics Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Alzheimer Disease with a site in Netherlands — 16 open to participants now, 27 under way, 9 of them phase 3. Alzheimer Disease · Netherlands.

Planned enrollment
82nd of 119
68 · median 241
Started
2026
with 3 others
Phase 1
22 of 133
4 open now
Primary completion
2027-02
later than 10 of 26 live
Registered
132nd of 133
by date

Among the 133 studies in Alzheimer Disease with a site in Netherlands, this one is the 82nd largest by planned enrollment of the 119 interventional ones that give a count, is one of 4 that started in 2026, is one of 22 in phase 1, reaches primary completion later than 10 of the 26 other live ones, and was the 132nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

16 of the 133 studies in Alzheimer Disease with a site in Netherlands are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Alzheimer Disease with a site in Netherlands, or all of them as a file.
02

Study summary

This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment, or mild AD with biomarker evidence of amyloid positivity.

Note: In the Netherlands, this study includes an open-label extension.

03

Conditions studied

  • Alzheimer Disease, Early Onset

Browse trials for

Keywords

  • Alzheimer's Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • of ≥18 to \< 32 kg/m2 and body weight of ≥45 kg
  • Have a diagnosis of probable AD dementia based on NIA AA 2011 criteria, including amnestic or nonamnestic presentation at screening
  • Have supportive evidence of AD pathology via historical records or laboratory testing at screening for amyloid positivity
  • Have AD severity defined as the following at screening:

    • A Clinical Dementia Rating global score of 0.5 or 1
    • A score of 20 to 30 (inclusive)

Key Exclusion Criteria:

  • Have neurological or cognitive disorders affecting the CNS other than AD, as determined by the investigator
  • Have clinically significant psychiatric conditions
  • Have any history of unstable or poorly controlled endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, hematological, or other significant medical condition that, in the opinion of the investigator, may interfere with the completion or interpretation of study assessment
  • Have had a within 5 years before screening, except fully resected basal cell carcinoma or other malignancies (such as prostate cancer) at low risk of recurrence, depending on investigator and medical monitor agreement
  • Have had previous anti amyloid or anti tau immunotherapy (including active immunization)

    • Note: ADAD participants who have participated in previous passive anti-amyloid immunotherapy > 6 months previously will be allowed, contingent on investigator and Sponsor agreement
  • Have had previous exposure to gene therapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    Drug: DNL628

  • Placebo comparator
    Placebo Arm

    Drug: Placebo

Interventions

  • DrugDNL628

    Multiple ascending doses

  • DrugPlacebo

    Multiple ascending doses

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events (TEAEs) throughout the double-blind period

    Time frame: 37 weeks

Secondary outcomes

  1. PK parameter: Maximum concentration (Cmax) of DNL628 in plasma

    Time frame: 37 weeks

  2. PK Parameter: Time to reach maximum concentration (tmax) of DNL628 in plasma

    Time frame: 37 weeks

  3. PK Parameter: Minimum concentration (Cmin) of DNL628 in plasma

    Time frame: 37 weeks

  4. PK Parameter: Area under the concentration-time curve (AUC) from time zero to time of last measurable concentration (AUClast) of DNL628 in plasma

    Time frame: 37 weeks

  5. PK Parameter: AUC from time 0 to the end of the dosing interval (AUCτ) of DNL628 in plasma

    Time frame: 37 weeks

  6. PK Parameter: terminal elimination half-life (t1/2) of DNL628 in plasma

    Time frame: 37 weeks

  7. PK Parameter: Accumulation ratio of DNL628 in plasma

    Time frame: 37 weeks

  8. Change from baseline in total tau and ptau181 as measured in CSF

    Time frame: 25 weeks

07

Study locations

4 of 4 sites recruiting
  • Clinical Site(s)
    's-Hertogenbosch, Netherlands
    Recruiting
  • Clinical Site(s)
    Amsterdam, Netherlands
    Recruiting
  • Clinical Site(s)
    Zwolle, Netherlands
    Recruiting
  • Clinical Site(s)
    London, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Feb 2027, 13 months after the start.

Of 163 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 13 months is close to that.

Counting every sponsor, half of 236 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2025
First posted
Jan 9, 2026
StartActual
Jan 30, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07328451
Lead sponsor
Denali Therapeutics Inc.
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Jan 30, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Clinical Trials at Denali Therapeutics
Contact
clinical-trials@dnli.com
Email:
Medical Monitor
study director · Denali Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion